Billings Clinic
Especially For:

Clinical Trials

Title   Myelodysplastic Syndrome (E2905) Low or Intermediate Risk
Description   Randomized Phase III Trial Comparing the Frequency fo Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) alone and in Combination with Epoetin Alfa (Procrit) in subjects with Low or Intermediate Risk MDS and Symptomatic Anemia
IRB Number   CTSU E2905
Category   Myelodyplastic Syndrome
Inclusion/Notes   MDS for 3 mos or more
Symptomatic Anemia
Age 18 or older

Status   Active
Start Date   03/13/2009
Principal Investigator (PI)   Jorge Nieva, MD
Physician Profile   Hematology/Oncology
Contact Name   Linda Allen RN
Contact Email   lallen@billingsclin
Phone   (406) 435-7484
Alternate Phone   (406) 435-7480
Fax   (406) 435-7489
Funding Source   NCI
Print This Page
Email to a Friend
Home | Contact | Site Map | Site Privacy Policy | Terms & Conditions | Patient Privacy Policy | Medical Records | Fast Command
2800 10th Ave. North | P.O. Box 37000 | Billings, Montana 59107 | 406.238.2500
© Copyright 2014 Billings Clinic. All Rights Reserved.